Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DT 9081

Next Previous
Drug Profile

DT 9081

Alternative Names: DT 095895; DT-9081

Latest Information Update: 06 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Domain Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 24 Nov 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Recurrent) in France, Belgium (PO) (NCT05582850)
  • 19 Oct 2022 Domain Therapeutics plans a clinical trial in Solid tumour in France and Belgium by the end of 2022
  • 19 Oct 2022 ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) in Belgium approves IND application for DT 9081 in solid tumors

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top